Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
IPO Year: 2021
Exchange: NASDAQ
Website: lavatherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/25/2022 | $9.00 | Buy | H.C. Wainwright |
| 11/16/2021 | $24.00 → $20.00 | Outperform | SVB Leerink |
| 8/17/2021 | $26.00 → $24.00 | Outperform | SVB Leerink |
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. "These dose-escalation data from the first four cohorts of our Phase 1/2a clinical tria
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual Global Investment Conference. Presentation DetailsFormat: Fireside ChatDate: Monday, September 9, 2024Time: 3:30 PM ET A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for LAVA-1207Next data update for LAVA-1207 program expected in Q4 2024Strong balance sheet with cash of $86.8 million supports runway into mid-2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 3
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. Presentation Details Format: Fireside Chat Date: Tuesday, June 25, 2024Time: 9:30 AM ET A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavather
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 19, 2024 at 2:00 pm CEST. All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are available in the "Investors" section of LAVA's website (www.lavatherapeutics.com) under "Annual Meeting." The documents will also be made available on the SEC's we
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or "Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Presentation Details Format: Fireside ChatDate: Wednesday, June 5, 2024Time: 8:00 a.m. ET A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at h
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1LAVA-1266 on track for Q2 2024 IND submissionStrong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or "Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference. Presentation Details Format: Fireside ChatDate: Monday, May 13, 2024Time: 10:00 a.m. ET A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at htt
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) LAVA 1266 tracking to Q2 2024 IND submission Strong balance sheet with cash of $95.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced recent corporate highlights and financial result
UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Pfizer has achieved a clinical development milestone for PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone payment of $7 Million to LAVA. LAVA granted Seagen (acquired by Pfizer in December 2023) a worldwide, exclusive license to PF-08046052 in September 2022. "We are very pleased with the initiation of clinical development by Pfizer of PF-08046052, formerly SGN-EGFRd2/LAVA-1223.
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in combination with LAVA-1207, a Gammabody® designed to target the prostate-specific membrane antigen (PSMA) to trigger the potent and preferential killing of PSMA-positive tumor cell
6-K - LAVA Therapeutics NV (0001840748) (Filer)
6-K - LAVA Therapeutics NV (0001840748) (Filer)
6-K - LAVA Therapeutics NV (0001840748) (Filer)
6-K - LAVA Therapeutics NV (0001840748) (Filer)
6-K - LAVA Therapeutics NV (0001840748) (Filer)
20-F - LAVA Therapeutics NV (0001840748) (Filer)
6-K - LAVA Therapeutics NV (0001840748) (Filer)
6-K - LAVA Therapeutics NV (0001840748) (Filer)
6-K - LAVA Therapeutics NV (0001840748) (Filer)
6-K - LAVA Therapeutics NV (0001840748) (Filer)
HC Wainwright & Co. analyst Arthur He reiterates LAVA Therapeutics (NASDAQ:LVTX) with a Buy and maintains $6 price target.
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.12) by 83.33 percent. This is a 96.23 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $6.99 million which missed the analyst consensus estimate of $7.00 million by 0.11 percent. This is a 471.24 percent increase over sales of $1.22 million the same period last year.
HC Wainwright & Co. analyst Arthur He reiterates LAVA Therapeutics (NASDAQ:LVTX) with a Buy and maintains $6 price target.
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.12) by 100 percent. This is a 57.89 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $353.00 thousand which missed the analyst consensus estimate of $6.25 million by 94.35 percent. This is a 86.63 percent decrease over sales of $2.64 million the same period last year.
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance to uncover new information. This index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors or casual readers should watch them. Here is a look at the Benzinga Stock Whisper Index for the week of Jan. 26: American Airlines Group (NASDAQ:AAL): The airline
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&P 500 also rose, gaining, 0.26% to 4,881.28. Check This Out: How To Earn $500 A Month From Capital One Financial Ahead Of Its Q4 Earnings Report Leading and Lagging Sectors Communication services shares rose by 1.5% on Thursday. In trading on Thursday, consumer discretionary shares fell by 1.4%. Top Headline Tesla, Inc. (NASDAQ:TSLA) shares dipped more than 12% on Thursday after the company reported worse-than-expected fourth-quarter financial results. Tesla reported fou
SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)
SC 13D - LAVA Therapeutics NV (0001840748) (Subject)
SC 13G - LAVA Therapeutics NV (0001840748) (Subject)
H.C. Wainwright initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $9.00
SVB Leerink reiterated coverage of LAVA Therapeutics with a rating of Outperform and set a new price target of $20.00 from $24.00 previously
SVB Leerink reiterated coverage of LAVA Therapeutics with a rating of Outperform and set a new price target of $24.00 from $26.00 previously
JP Morgan initiated coverage of LAVA Therapeutics with a rating of Overweight and set a new price target of $22.00
Jefferies initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $23.00
SVB Leerink initiated coverage of LAVA Therapeutics with a rating of Outperform and set a new price target of $26.00
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board. "As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three deca
UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. "During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals," said Stephen Hurly, president and chief executive offi
LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclinical bispecific gamma delta T cell engager for EGFR-expressing solid tumorsCash and investments of $92.7 million as of September 30, 2022, plus$50.0 million received from Seagen in October provide cas
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the appointment of Fred M. Powell as Chief Financial Officer, effective today. Mr. Powell brings over 20 years of global CFO experience in the biopharmaceutical industry, including investor relations, administration, operations and information technology. "I am pleased to welcome Fred to LAVA's executive team. He brings extensive expertise in financial leadership and is a seasoned executive having served as a CFO for sev
Forbion Appoints Nanna Lüneborg as a General Partner - Brings extensive international investment and board experience in life sciences companies of all sizes including company creations, private venture deals and IPOs - Naarden, The Netherlands, 1 September 2021 – Forbion, a leading European life sciences venture capital firm, today announces the appointment of Nanna Lüneborg, PhD as a General Partner to work on the €360m Forbion Growth Opportunities Fund. Prior to joining Forbion, Nanna was a Partner at Novo Ventures and a key member of the European deal team focussing on late-stage biopharma investments across Europe. During her 10 years at Novo, Nanna was involved in numerous success
Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant prostate cancer; on track to begin later this year Collaboration with Janssen Biotech, Inc. remains on track and progressing towards potential milestones Cash balance of $151 million expected to fund operations into the second half of 2023 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers (bsTCEs) to transform the t
UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced the appointment of Amy Garabedian as general counsel and corporate secretary. Ms. Garabedian is a seasoned leader with extensive corporate and transactional expertise within the life science industry. "We are very pleased to welcome Amy to our executive team. Amy's proven experience across a wide range of complex strategic legal and corporate matters in life sciences will be invaluable as our differentiated pipeline of bis